Editorial: Development and validation of new molecular probes of nuclear medicine and new targets of nuclear drugs in cancers
Frontiers in Oncology · 16.03.2026 · 16
DOI: 10.3389/fonc.2026.1812790 ↗Kurz gefasst
Editorial in der Zeitschrift Frontiers in Oncology, online erschienen am 16.03.2026. Verfasst von Wanying Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, China. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Medical Technology, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- Department of Nuclear Medicine, National Clinical Research Center for Cancer, Tianjin Cancer Hospital Airport Hospital, Tianjin, China.
- Department of Nuclear Medicine, Chongqing University Cancer Hospital, Chongqing, China.
- Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, El Paso, TX, United States.
- Department of Molecular Imaging and Nuclear Medicine, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Zitieren
APA
Li, W., Wang, Z., Chen, X., Qin, Y., & Dai, D. (2026). Editorial: Development and validation of new molecular probes of nuclear medicine and new targets of nuclear drugs in cancers. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1812790
Vancouver
Li W, Wang Z, Chen X, Qin Y, Dai D. Editorial: Development and validation of new molecular probes of nuclear medicine and new targets of nuclear drugs in cancers. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1812790
BibTeX
@article{Li2026,
author = {Li, Wanying and Wang, Ziyang and Chen, Xiaoliang and Qin, Yong and Dai, Dong},
title = {Editorial: Development and validation of new molecular probes of nuclear medicine and new targets of nuclear drugs in cancers},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1812790}
}
EUVIMED